2.76
-0.11 (-3.83%)
| Penutupan Terdahulu | 2.87 |
| Buka | 2.87 |
| Jumlah Dagangan | 25,701 |
| Purata Dagangan (3B) | 49,983 |
| Modal Pasaran | 88,547,600 |
| Harga / Buku (P/B) | 1.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Mar 2026 |
| EPS Cair (TTM) | -19.29 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.23% |
| Nisbah Semasa (MRQ) | 7.43 |
| Aliran Tunai Operasi (OCF TTM) | -12.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.01 M |
| Pulangan Atas Aset (ROA TTM) | -19.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.48% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Dogwood Therapeutics, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.07% |
| % Dimiliki oleh Institusi | 7.95% |
| Julat 52 Minggu | ||
| Median | 12.00 (334.78%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Feb 2026 | 12.00 (334.78%) | Beli | 2.93 |
| 30 Jan 2026 | 12.00 (334.78%) | Beli | 2.79 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 |
| 12 Jan 2026 | Pengumuman | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |